Aeglea Bio Therapeutics (NASDAQ:AGLE) Raised to “Strong-Buy” at ValuEngine

ValuEngine upgraded shares of Aeglea Bio Therapeutics (NASDAQ:AGLE) from a buy rating to a strong-buy rating in a research note published on Thursday morning, ValuEngine reports.

Separately, HC Wainwright restated a buy rating and set a $20.00 price objective on shares of Aeglea Bio Therapeutics in a research report on Monday, June 3rd. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $14.33.

Shares of AGLE stock opened at $8.94 on Thursday. Aeglea Bio Therapeutics has a 1 year low of $5.99 and a 1 year high of $11.16. The company’s 50 day moving average is $6.99.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts predict that Aeglea Bio Therapeutics will post -2.14 EPS for the current year.

In related news, CEO Anthony G. Quinn acquired 31,905 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were acquired at an average cost of $6.16 per share, for a total transaction of $196,534.80. Following the completion of the transaction, the chief executive officer now directly owns 333,955 shares in the company, valued at approximately $2,057,162.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Anthony G. Quinn acquired 6,218 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were bought at an average price of $6.65 per share, for a total transaction of $41,349.70. Following the completion of the transaction, the chief executive officer now owns 277,152 shares of the company’s stock, valued at $1,843,060.80. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 92,177 shares of company stock worth $593,817. Company insiders own 12.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. grew its stake in shares of Aeglea Bio Therapeutics by 38.4% during the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,967 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Aeglea Bio Therapeutics by 11.9% during the first quarter. Rhumbline Advisers now owns 24,130 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 2,559 shares during the last quarter. BNP Paribas Arbitrage SA bought a new position in shares of Aeglea Bio Therapeutics during the first quarter valued at approximately $32,000. Bank of New York Mellon Corp grew its stake in shares of Aeglea Bio Therapeutics by 11.6% during the fourth quarter. Bank of New York Mellon Corp now owns 49,470 shares of the biotechnology company’s stock valued at $371,000 after buying an additional 5,150 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Aeglea Bio Therapeutics by 5.4% during the fourth quarter. Geode Capital Management LLC now owns 162,597 shares of the biotechnology company’s stock valued at $1,217,000 after buying an additional 8,310 shares during the last quarter. 68.47% of the stock is currently owned by hedge funds and other institutional investors.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Featured Article: What is Call Option Volume?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.